YOLT-201
Phase 1Small molecule
YOLT-201 is one of 40 small molecule programs targeting Cardiomyopathy. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Dobutrex
Eli LillyPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Wainua (autoinjector)
AstraZenecaPhase 3
Immunoglobulins
CSL BehringPhase 3
Cialis
Eli LillyPhase 2
Aldactone
PfizerPhase 2
Betaseron
BayerPhase 2
Cellcept
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiomyopathy2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YOLT-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- YYolTech Therapeutics Co., Ltd